Panbela Therapeutics, Inc.
PBLA
$0.2603
-$0.0607-18.91%
OTC PK
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.11M | 1.11M | 1.20M | 931.00K | 1.11M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.17M | 8.10M | 6.73M | 7.04M | 7.85M |
| Operating Income | -7.17M | -8.10M | -6.73M | -7.04M | -7.85M |
| Income Before Tax | -7.17M | -7.14M | -7.26M | -6.49M | -7.85M |
| Income Tax Expenses | -- | -- | -138.00K | -19.00K | -19.00K |
| Earnings from Continuing Operations | -7.17M | -7.14M | -7.12M | -6.47M | -7.83M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -7.17M | -7.14M | -7.12M | -6.47M | -7.83M |
| EBIT | -7.17M | -8.10M | -6.73M | -7.04M | -7.85M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -1.48 | -1.47 | -2.28 | -65.82 | -53.74 |
| Normalized Basic EPS | -0.92 | -1.02 | -1.45 | -17.11 | -35.39 |
| EPS Diluted | -1.48 | -1.47 | -2.28 | -65.82 | -53.74 |
| Normalized Diluted EPS | -0.92 | -1.02 | -1.45 | -17.11 | -35.39 |
| Average Basic Shares Outstanding | 4.85M | 4.85M | 3.13M | 237.20K | 145.70K |
| Average Diluted Shares Outstanding | 4.85M | 4.85M | 3.13M | 237.20K | 145.70K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |